Literature DB >> 9236412

Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited.

J C Cleveland1, D R Meldrum, B S Cain, A Banerjee, A H Harken.   

Abstract

BACKGROUND: Patients receiving oral hypoglycemic agents for diabetes mellitus are at increased risk of cardiovascular mortality. Oral hypoglycemic agents are inhibitors of the ATP-sensitive potassium (KATP) channel. Ischemic preconditioning is mediated by KATP channel activation. We therefore hypothesized that myocardium from patients taking long-term oral hypoglycemic agents would be resistant to the protection by ischemic preconditioning. METHODS AND
RESULTS: Isolated human right atrial trabeculae were suspended in an organ bath at 37 degrees C, with field stimulation at 1 Hz. Control trabeculae were then subjected to 45 minutes of simulated ischemia (hypoxic, glucose-free buffer with pacing at 3 Hz) and 120 minutes of reperfusion. Ischemic preconditioned (IPC) trabeculae from patients without oral hypoglycemic therapy and from patients taking insulin (Ins+IPC) were given 5 minutes of simulated ischemia before this injury. Trabeculae (Oral Hypo+IPC) were obtained from patients taking long-term oral hypoglycemic agents and were also exposed to 5 minutes of simulated ischemia before this injury. Developed force (DF) was recorded. Recovery of DF relative to preischemic values was 28 +/- 4% in control trabeculae, whereas IPC trabeculae showed 52 +/- 5% recovery (P < .05 versus control). In patients receiving long-term oral hypoglycemic agents (Oral Hypo+IPC), recovery of DF was 27 +/- 3%, but in trabeculae from insulin-treated patients (Ins+IPC), it was 45 +/- 6%.
CONCLUSIONS: Human myocardium from patients without long-term exposure to oral hypoglycemic agents is functionally protected by preconditioning. Long-term oral hypoglycemic intake blocks the protection by preconditioning. These data suggest that ischemic preconditioning in human myocardium relies on KATP channels, and long-term inhibition of KATP channels with oral hypoglycemic agents may explain the excess cardiovascular mortality in these patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9236412     DOI: 10.1161/01.cir.96.1.29

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  47 in total

1.  Factors mediating remote preconditioning of trauma in the rat heart: central role of the cytochrome p450 epoxygenase pathway in mediating infarct size reduction.

Authors:  Garrett J Gross; Anna Hsu; Eric R Gross; John R Falck; Kasem Nithipatikom
Journal:  J Cardiovasc Pharmacol Ther       Date:  2012-03-09       Impact factor: 2.457

Review 2.  Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?

Authors:  J J Meier; B Gallwitz; W E Schmidt; A Mügge; M A Nauck
Journal:  Heart       Date:  2004-01       Impact factor: 5.994

Review 3.  Percutaneous coronary intervention in diabetics.

Authors:  Juhana Karha; Deepak L Bhatt
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

4.  Insulin suppresses ischemic preconditioning-mediated cardioprotection through Akt-dependent mechanisms.

Authors:  Tanner M Fullmer; Shaobo Pei; Yi Zhu; Crystal Sloan; Robert Manzanares; Brandon Henrie; Karla M Pires; James E Cox; E Dale Abel; Sihem Boudina
Journal:  J Mol Cell Cardiol       Date:  2013-08-30       Impact factor: 5.000

Review 5.  Regulation of ion channels in myocardial cells and protection of ischemic myocardium.

Authors:  N Sperelakis; M Sunagawa; H Yokoshiki; T Seki; M Nakamura
Journal:  Heart Fail Rev       Date:  2000-06       Impact factor: 4.214

Review 6.  Potential of glucose-lowering drugs to reduce cardiovascular events.

Authors:  Stuart W Zarich
Journal:  Curr Diab Rep       Date:  2009-02       Impact factor: 4.810

7.  Ameliorative potential of conditioning on ischemia-reperfusion injury in diabetes.

Authors:  Ashish K Rehni; Kunjan R Dave
Journal:  Cond Med       Date:  2018-04-20

8.  Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 2 diabetes.

Authors:  S B Kristiansen; B Løfgren; N B Støttrup; D Khatir; J E Nielsen-Kudsk; T T Nielsen; H E Bøtker; A Flyvbjerg
Journal:  Diabetologia       Date:  2004-10-07       Impact factor: 10.122

Review 9.  Are sulfonylureas passé?

Authors:  Jennifer B Green; Mark N Feinglos
Journal:  Curr Diab Rep       Date:  2006-11       Impact factor: 4.810

Review 10.  Impact of hypoglycemic agents on myocardial ischemic preconditioning.

Authors:  Rosa Maria Rahmi Garcia; Paulo Cury Rezende; Whady Hueb
Journal:  World J Diabetes       Date:  2014-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.